Shanghai Junshi Biosciences (HKG:1877, SHA:688180) said its experimental dermatology drug JS005 achieved "positive results" in a phase 3 clinical trial, according to a Hong Kong bourse filing Sunday.
Shares of the biopharmaceutical firm gained over 1% in morning trade Monday.
The drug met its co-primary endpoints and key secondary endpoints in the treatment of moderate to severe plaque psoriasis, a skin condition.
The company now plans to seek regulatory approval of the drug in the near future.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.